195 related articles for article (PubMed ID: 23226780)
21. Differential gene methylation in undifferentiated nasopharyngeal carcinoma.
Wong TS; Tang KC; Kwong DL; Sham JS; Wei WI; Kwong YL; Yuen AP
Int J Oncol; 2003 Apr; 22(4):869-74. PubMed ID: 12632081
[TBL] [Abstract][Full Text] [Related]
22. Methylation analysis of tumor suppressor genes in endometroid carcinoma of endometrium using MS-MLPA.
Dvorakova E; Chmelarova M; Laco J; Palicka V; Spacek J
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2013 Dec; 157(4):298-303. PubMed ID: 23736679
[TBL] [Abstract][Full Text] [Related]
23. Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma.
Morrissey C; Martinez A; Zatyka M; Agathanggelou A; Honorio S; Astuti D; Morgan NV; Moch H; Richards FM; Kishida T; Yao M; Schraml P; Latif F; Maher ER
Cancer Res; 2001 Oct; 61(19):7277-81. PubMed ID: 11585766
[TBL] [Abstract][Full Text] [Related]
24. Clinical significance of hypermethylation status in NSCLC: evaluation of a 30-gene panel in patients with advanced disease.
Pesek M; Kopeckova M; Benesova L; Meszarosova A; Mukensnabl P; Bruha F; Minarik M
Anticancer Res; 2011 Dec; 31(12):4647-52. PubMed ID: 22199344
[TBL] [Abstract][Full Text] [Related]
25. Promoter methylation status of HIN-1 associated with outcomes of ovarian clear cell adenocarcinoma.
Ho CM; Huang CJ; Huang CY; Wu YY; Chang SF; Cheng WF
Mol Cancer; 2012 Aug; 11():53. PubMed ID: 22871047
[TBL] [Abstract][Full Text] [Related]
26. Genetic Analysis Reveals the Important Role of the
Lai YC; Wang WC
Anticancer Res; 2021 Sep; 41(9):4295-4304. PubMed ID: 34475049
[TBL] [Abstract][Full Text] [Related]
27. Concurrent methylation of promoters from tumor associated genes predicts outcome in acute myeloid leukemia.
Hess CJ; Errami A; Berkhof J; Denkers F; Ossenkoppele GJ; Nygren AO; Schuurhuis GJ; Waisfisz Q
Leuk Lymphoma; 2008 Jun; 49(6):1132-41. PubMed ID: 18569637
[TBL] [Abstract][Full Text] [Related]
28. DNA hypermethylation, Her-2/neu overexpression and p53 mutations in ovarian carcinoma.
Feng Q; Deftereos G; Hawes SE; Stern JE; Willner JB; Swisher EM; Xi L; Drescher C; Urban N; Kiviat N
Gynecol Oncol; 2008 Nov; 111(2):320-9. PubMed ID: 18757082
[TBL] [Abstract][Full Text] [Related]
29. Frequent promoter hypermethylation of BRCA2, CDH13, MSH6, PAX5, PAX6 and WT1 in ductal carcinoma in situ and invasive breast cancer.
Moelans CB; Verschuur-Maes AH; van Diest PJ
J Pathol; 2011 Oct; 225(2):222-31. PubMed ID: 21710692
[TBL] [Abstract][Full Text] [Related]
30. Methylation profiles of endometrioid and serous endometrial cancers.
Seeber LM; Zweemer RP; Marchionni L; Massuger LF; Smit VT; van Baal WM; Verheijen RH; van Diest PJ
Endocr Relat Cancer; 2010 Sep; 17(3):663-73. PubMed ID: 20488783
[TBL] [Abstract][Full Text] [Related]
31. Promoter hypermethylation profile of ovarian epithelial neoplasms.
Makarla PB; Saboorian MH; Ashfaq R; Toyooka KO; Toyooka S; Minna JD; Gazdar AF; Schorge JO
Clin Cancer Res; 2005 Aug; 11(15):5365-9. PubMed ID: 16061849
[TBL] [Abstract][Full Text] [Related]
32. Promoter hypermethylation in male breast cancer: analysis by multiplex ligation-dependent probe amplification.
Kornegoor R; Moelans CB; Verschuur-Maes AH; Hogenes MCh; de Bruin PC; Oudejans JJ; van Diest PJ
Breast Cancer Res; 2012 Jul; 14(4):R101. PubMed ID: 22765268
[TBL] [Abstract][Full Text] [Related]
33. Oligodendroglial tumors frequently demonstrate hypermethylation of the CDKN2A (MTS1, p16INK4a), p14ARF, and CDKN2B (MTS2, p15INK4b) tumor suppressor genes.
Wolter M; Reifenberger J; Blaschke B; Ichimura K; Schmidt EE; Collins VP; Reifenberger G
J Neuropathol Exp Neurol; 2001 Dec; 60(12):1170-80. PubMed ID: 11764089
[TBL] [Abstract][Full Text] [Related]
34. Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis.
Clifford SC; Prowse AH; Affara NA; Buys CH; Maher ER
Genes Chromosomes Cancer; 1998 Jul; 22(3):200-9. PubMed ID: 9624531
[TBL] [Abstract][Full Text] [Related]
35. Monitoring of methylation changes in 9p21 region in patients with myelodysplastic syndromes and acute myeloid leukemia.
Cechova H; Lassuthova P; Novakova L; Belickova M; Stemberkova R; Jencik J; Stankova M; Hrabakova P; Pegova K; Zizkova H; Cermak J
Neoplasma; 2012; 59(2):168-74. PubMed ID: 22248274
[TBL] [Abstract][Full Text] [Related]
36. Aberrant Promoter Hypermethylation of RASSF1a and BRCA1 in Circulating Cell-Free Tumor DNA Serves as a Biomarker of Ovarian Carcinoma.
S SK; Swamy SN; Premalatha CS; Pallavi VR; Gawari R
Asian Pac J Cancer Prev; 2019 Oct; 20(10):3001-3005. PubMed ID: 31653147
[TBL] [Abstract][Full Text] [Related]
37. Hypermethylation of CDKN2A exon 2 in tumor, tumor-adjacent and tumor-distant tissues from breast cancer patients.
Spitzwieser M; Entfellner E; Werner B; Pulverer W; Pfeiler G; Hacker S; Cichna-Markl M
BMC Cancer; 2017 Apr; 17(1):260. PubMed ID: 28403857
[TBL] [Abstract][Full Text] [Related]
38. Epigenetic events of disease progression in head and neck squamous cell carcinoma.
Worsham MJ; Chen KM; Meduri V; Nygren AO; Errami A; Schouten JP; Benninger MS
Arch Otolaryngol Head Neck Surg; 2006 Jun; 132(6):668-77. PubMed ID: 16785414
[TBL] [Abstract][Full Text] [Related]
39. Promoter hypermethylation in ductal carcinoma in situ of the male breast.
Vermeulen MA; van Deurzen CHM; Doebar SC; de Leng WWJ; Martens JWM; van Diest PJ; Moelans CB
Endocr Relat Cancer; 2019 Jun; 26(6):575-584. PubMed ID: 30921768
[TBL] [Abstract][Full Text] [Related]
40. Epigenetic progression of columnar cell lesions of the breast to invasive breast cancer.
Verschuur-Maes AH; de Bruin PC; van Diest PJ
Breast Cancer Res Treat; 2012 Dec; 136(3):705-15. PubMed ID: 23104224
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
